Remove 2020 Remove Diagnosis Remove Individual Remove Provider
article thumbnail

Insights into the design, development and implementation of a novel digital health tool for skilled birth attendants to support quality maternity care in Kenya

BMJ

doi: 10.1136/fmch-2020-000845 The appetite for and ability to collect accurate digital patient-level data in low-resource settings has fueled numerous massive global health initiatives. As impressive as these large numbers may be, the question that is less often asked is “How much of that big data is actually helping us do better?”

article thumbnail

COVID At-Home Antigen Tests: If at First You Don’t Succeed Try, Try and Try Again

FDA Law Blog

These practical benefits are in marked contrast to molecular COVID-19 tests that are used for definitive diagnosis and are generally expected to detect the SARS-CoV-2 virus at least 95% of the time when someone is infected. After two negative tests, you should consider a molecular test, or call your healthcare provider.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

A portrait of primary care use in community dwelling persons with dementia in Quebec between 2018 and 2020 [Health care disparities]

Annals of Family Medicine

Objective To provide a comprehensive overview of primary care use among community-dwelling persons with dementia in Quebec from 2018 to 2020. Population Studied Community-dwelling persons aged 65 and older with a prevalent diagnosis of dementia on March 1st of 2018, 2019, and 2020. 60.8%, 60.2%, and 58.8%

article thumbnail

Out At Home: FDA’s Vocal Support of Home Testing but Reluctance to Clear Novel OTC Home Tests

FDA Law Blog

Regarding COVID-19, Tim Stenzel, Director of CDRH’s Office of In Vitro Diagnostics, has stated that “in-home testing and home collections is a top priority” ( June 2020 FDA Virtual Town Hall ); “obviously home over-the-counter tests including rapid antigen tests are a high priority” ( February 2021 FDA Virtual Town Hall ). seeking treatment).

article thumbnail

Diabetes in Late Life: Nadine Carter, Tamryn Gray, Alex Lee

GeriPal

So a lot of these patients that I care for are at risk for mortality or poor prognosis in general, and wanting to know how do we still provide them with quality care without giving them too many pricks, too many titrations when it comes to insulin. Overwhelming people with just a lot of data is big.

article thumbnail

Telehealth vs In-Person Palliative Care: A Podcast with Joseph Greer, Lynn Flint, Simone Rinaldi, and Vicki Jackson

GeriPal

But in reality, given workforce shortages and just the challenges and the resources necessary to be able to provide early integrated palliative care from the time of diagnosis of advanced cancer, the model simply is not implementable, at least not in our current state with our available infrastructure and resources. Eric 10:25 Great.

article thumbnail

CMS Publishes Grab Bag of Proposed Changes to the Medicaid Drug Rebate Program

FDA Law Blog

For 10 high-cost single source covered outpatient drugs selected annually by CMS, manufacturers would be required to respond to a so-called “price verification survey” by providing not only clinical and utilization information about the drug, but also costs of production, distribution, research, and marketing; revenue and profit; and ex-U.S.